December 04, 2025

Universität Heidelberg: Outstanding Placings in Shanghai Ranking of Academic Subjects

Universität Heidelberg: Outstanding Placings in Shanghai Ranking of Academic Subjects

Clinical medicine and medical technology internationally in 18th position – top placements for biological sciences and human biological sciences

With clinical medicine and medical technology, Heidelberg University is among the best representatives of the medical sciences worldwide. In the 2025 Global Ranking of Academic Subjects, both rank 18th internationally. Clinical medicine thus continues to hold the top position in Germany, while medical technology takes third place. The biological sciences are once again at the top of the list in Germany, ranking 39th worldwide.

Human biological sciences in Heidelberg are also among the “top 50” in the world in their subject area. Like the biological sciences, they are classed in the field of life sciences and, after jumping from the 51 to 75 ranking group, now rank 44th internationally, which means third place in Germany. The “top 100” subjects in the natural sciences include physics at Heidelberg University, which has moved up from the 76 to 100 ranking group to the 51 to 75 ranking group and now takes second place nationally.

The ranking of subjects appeared in November 2025 and is part of the Academic Ranking of World Universities, also called the Shanghai Ranking. The subjects are grouped into five academic fields and evaluated according to nine indicators. These include mainly publication data and the prizes and awards won at a university, as well as the number of most-cited researchers or editors in international journals, among other things. The individual indicators are applied in five different categories and are weighted differently depending on the subject.

In the overall Shanghai Ranking published in August this year, Heidelberg University took third place in Germany, ranking 16th in Europe and 51st internationally.

Further information

Our latest News

discover more
AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

NORTH CHICAGO, Ill., July 6, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 […]

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

It should be biofunctional – that is, it should replicate the natural cellular environment as closely as possible – and it should be printable: bioink. Achieving both of these properties at the same time is an enormous challenge that conventional biomaterials often fail to meet. Together with two partner companies, researchers at the NMI have now taken an important […]

New AI System Provides Treatment Recommendations for Complex Blood Cancers

New AI System Provides Treatment Recommendations for Complex Blood Cancers

Researchers from the German Cancer Research Center (DKFZ), the HI-STEM* Stem Cell Institute, and the Heidelberg University Hospital (UKHD) have developed “HemaGuide,” an AI assistant that supports physicians in making difficult treatment decisions. In extensive testing, the system has shown a high degree of agreement with the recommendations of experienced experts and could significantly improve […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp